Daewon Pharm
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more
Daewon Pharm (003220) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.065x
Based on the latest financial reports, Daewon Pharm (003220) has a cash flow conversion efficiency ratio of -0.065x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-17.26 Billion) by net assets (₩263.87 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Daewon Pharm - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Daewon Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Daewon Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daewon Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unibel S.A
PA:UNBL
|
0.077x |
|
Krishana Phoschem Limited
NSE:KRISHANA
|
0.131x |
|
KALTURA INC. DL -0001
F:73Q
|
N/A |
|
Verkkokauppa.com Oyj
HE:VERK
|
-0.010x |
|
Fineotex Chemical Limited
NSE:FCL
|
0.026x |
|
MYFAIR GOLD CORP.
F:9M5
|
N/A |
|
Shenzhen L&A Design Holding Limited
SHE:300949
|
N/A |
|
Barton Gold Holdings Ltd
AU:BGD
|
-0.172x |
Annual Cash Flow Conversion Efficiency for Daewon Pharm (2011–2024)
The table below shows the annual cash flow conversion efficiency of Daewon Pharm from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩284.58 Billion | ₩30.04 Billion | 0.106x | -46.09% |
| 2023-12-31 | ₩264.26 Billion | ₩51.73 Billion | 0.196x | +46.13% |
| 2022-12-31 | ₩248.77 Billion | ₩33.33 Billion | 0.134x | +30.54% |
| 2021-12-31 | ₩218.40 Billion | ₩22.41 Billion | 0.103x | -12.49% |
| 2020-12-31 | ₩212.77 Billion | ₩24.95 Billion | 0.117x | -22.67% |
| 2019-12-31 | ₩204.22 Billion | ₩30.97 Billion | 0.152x | -30.60% |
| 2018-12-31 | ₩183.20 Billion | ₩40.03 Billion | 0.219x | +761.41% |
| 2017-12-31 | ₩168.13 Billion | ₩4.27 Billion | 0.025x | -80.23% |
| 2016-12-31 | ₩162.01 Billion | ₩20.79 Billion | 0.128x | -26.10% |
| 2015-12-31 | ₩148.66 Billion | ₩25.82 Billion | 0.174x | +33.89% |
| 2014-12-31 | ₩134.51 Billion | ₩17.45 Billion | 0.130x | +29.76% |
| 2013-12-31 | ₩123.25 Billion | ₩12.32 Billion | 0.100x | -18.36% |
| 2012-12-31 | ₩112.92 Billion | ₩13.83 Billion | 0.122x | -29.04% |
| 2011-12-31 | ₩103.92 Billion | ₩17.93 Billion | 0.173x | -- |